525 results about "Normal cell" patented technology

The invention discloses an AIE type fluorescent probe with tumor targeting as well as preparation and application thereof, and belongs to the technical field of medicines, the probe can accurately target HDAC6 high-expression tumor cells, the specific binding capacity of the probe reduces interference to normal cells, and the detection accuracy is improved. The probe is fused with AIE performance dye molecules and emits strong fluorescence during aggregation, so that the imaging sensitivity and definition are remarkably enhanced. By optimizing the structure and synthesis conditions, the fluorescence intensity and stability of the probe are improved, the sensitivity of early tumor detection is ensured, and the survival rate and life quality of patients are improved. The preparation method is simple, convenient, feasible, low in cost and beneficial to practical application. The probe can be used for preparing tumor detection products, assisting in tumor diagnosis and classification, monitoring treatment changes and evaluating the curative effect. High-precision imaging can be realized in the aspect of tumor imaging, the method can be used for evaluating curative effect and guiding formulation of subsequent treatment schemes, and the application prospect is wide.

The invention relates to the field of molecular targeted therapy, and discloses an application of an SLC16A5 (MCT6) small-molecule inhibitor MCT6-Ai7-2 in preparation of a medicine for treating acute myeloid leukemia (AML). The inhibitor takes an SLC16A5 protein structure predicted by Alphafold as a target spot, and is obtained through compound database screening, molecular docking and druggability optimization. An in-vitro experiment proves that MCT6-Ai7-2 can remarkably inhibit proliferation of AML cell lines such as U937 and MOLM-13, induce cell apoptosis and retard a cell cycle, has an inhibiting effect on a primary AML patient specimen and is relatively low in toxicity to normal cells; in-vivo experiments show that the compound is effective and has good safety in AML model mice. In addition, the MCT6-Ai7-2 and the vinca can be combined to synergistically enhance the inhibition effect on vinca drug-resistant cells, and by reducing the expression of anti-apoptotic protein MCL-1, the activation of pro-apoptotic factors BIM and tBID is promoted to play a role. The invention provides a novel targeting drug and strategy for treatment of AML (especially drug-resistant or recurrent patients).

The invention belongs to the field of anti-cancer metal complexes, and particularly relates to a copper complex with anti-cancer activity and a preparation method and application thereof. Cu (OAc) 2H2O and coumarin-3-formyl-(2-aminomethylpyridine) are respectively dissolved in a solvent, the two solutions are mixed and stirred at room temperature to react for a period of time, the reaction solution is filtered, the filtrate is sealed and naturally volatilized at room temperature for 3-7 days, the complex can be obtained, the IC50 value of the complex to Hela cervical cancer cells is 0.8964 + / -0.09 mu M, and the IC50 value of the complex to Hela cervical cancer cells is 0.8964 + / -0.09 mu M. According to the present invention, the inhibition effect of the complex on HeLa cervical cancer cells is 3.38 times of the inhibition effect of cis-platinum, the toxicity of the complex on normal cells but HUVEC is very small, IC50 is greater than 100 [mu] M, and the complex has a high selectivity coefficient SI (SI = normal cell IC50 / cancer cell IC50), and the selectivity coefficient SI is greater than 111 and is 584 times of the selectivity coefficient of cis-platinum (SI = 0.19). The complex has the capability of inducing apoptosis of cancer cells and has concentration dependence. Meanwhile, the complex can retard cancer cells and an S phase so as to inhibit cell proliferation, and can generate an intercalation effect with HS-DNA (High-Speed Deoxyribose Nucleic Acid).

The invention discloses a nucleic acid aptamer for accurate molecular typing of multi-parameter bladder cancer cells and application of the nucleic acid aptamer, and belongs to the technical field of biology. The technical problem to be solved in the invention is how to realize early accurate diagnosis of bladder cancer and molecular typing of bladder cancer in clinic. In order to solve the technical problem, the invention comprises nucleic acid aptamers including nucleic acid aptamers Seq12a, BCfsw1-3a, BCfsw1-4a, BCfsw1-10a, BCfsw2-19a and BCfsw2-19a, and a composition composed of the nucleic acid aptamers. According to the application, nucleic acid aptamer screening is carried out aiming at different levels of bladder cancer cells and bladder cancer clinical urine samples to obtain nucleic acid aptamer groups covering information of different types of bladder cancer, and cell molecular typing is realized on bladder cancer cells and normal cell lines; and the kit is preliminarily applied to clinical urine sample molecular typing and bladder cancer recurrence course monitoring.

The invention belongs to the technical field of biological medicine, and particularly discloses an antibody targeting ADAM17 protein and application of the antibody. The invention provides the ADAM17 specific target spot aiming at the malignant tumor of the biliary tract, the ADAM17 is highly expressed in the tumor of the biliary tract and is relatively low in expression in normal tissues, and by intervening the target spot, tumor cells can be killed, and non-specific attack to normal cells can be avoided as much as possible, so that the effectiveness and the safety of treating a patient with the malignant tumor of the biliary tract are improved. The invention also provides an antibody targeting ADAM17 protein and a preparation and screening method thereof, and the antibody can specifically recognize an antigen binding domain of ADAM17, has strong affinity with an ADAM17 antigen, and can be used for treating ADAM17 positive malignant tumors.

The invention discloses a multiple myeloma bone marrow image recognition system based on computer vision, relates to the technical field of cell recognition, solves the problem that traditional manual microscopic examination is large in limitation, and accurately recognizes burr change segments by conducting angle analysis on the edge contour of a feature area, so that the accuracy of recognition is improved. According to the comprehensive proportion of the burr change section on the overall edge contour, reliably judging whether the to-be-detected cell is a tumor cell or not, and calibrating and displaying the tumor cell in a gray image; according to the mode, the obvious difference of the tumor cells and normal cells in cell nucleus morphology is effectively utilized, rapid and accurate identification of the tumor cells is achieved, a visual and clear result is provided for clinical diagnosis, doctors are assisted to accurately judge multiple myeloma in time, the diagnosis efficiency and the treatment effect are improved, mean value processing and radial ratio analysis are conducted on contour area gray values, and the diagnosis accuracy is improved. The contour region associated with the cell nucleus can be accurately locked from the to-be-detected cell and is calibrated as the feature region, and a key cell nucleus feature basis is provided for tumor cell recognition.

The invention discloses an osthole compound, a metal complex and a preparation method and application of the osthole compound, the osthole compound (OST-Alkyne) has remarkable anti-tumor biological activity, osthole (OST) and a cyclometalated iridium precursor are further connected through a copper-catalyzed azide-alkyne cycloaddition (CuAAC) reaction, higher anti-tumor activity is shown, and the osthole compound has a good application prospect. Mitochondria is targeted, and tumor is killed by reducing mitochondrial membrane potential and inducing cell autophagy and necrotic apoptosis; according to the invention, natural products are combined with metals, so that not only are good selectivity and anti-proliferation ability to brain glioma cells realized, but also toxic and side effects to normal cells are overcome, a new design idea is provided for novel metal drugs to treat brain glioma, and the application prospect is wide.

Methods and systems for processing a scanned tissue section include locating cells within a scanned tissue. Cells in the scanned tissue are classified using a classifier model. A tumor-cell ratio (TCR) map is generated based on classified normal cells and tumor cells. A TCR isoline is generated for a target TCR value using the TCR map, marking areas of the tissue section where a TCR is at or above the target TCR value. Dissection is performed on the tissue sample to isolate an area identified by the isoline.

Processes of intraoperative diagnosis and elimination of tumors or micro-tumors or cancer cells or tumor micro-environment (TME) with plasmonic nanobubbles (PNBs) are disclosed. The diagnosis and surgical processes disclosed can improve standard onco-surgery through one or more of the following: real-time intraoperative local detection of MRD in vivo with high cancer sensitivity and specificity; real-time guidance of surgery to precisely eliminate resectable MRD with minimal morbidity by resecting only PNB-positive volume instead of a larger volume; intraoperative selective elimination of unresectable MRD through the mechanical impact of lethal cancer cell-specific PNBs without damaging adjacent normal cells and tissues; and prediction of the surgical outcome through the metrics of PNB signals.

The disclosure relates to an apparatus for diagnosing a battery of a vehicle, that may perform reliable diagnosis with respect to a voltage deviation of a battery of a vehicle, a battery diagnostic method thereof, and a vehicle system including the same. The apparatus for diagnosing a battery of a vehicle may include a voltage sensor measuring voltage with respect to a plurality of battery cells in the battery, and a processor diagnosing a voltage deviation of battery on the basis of the cell voltage measured by the voltage sensor. When the cell voltage deviation satisfies a voltage deviation diagnosis start condition, the processor determines whether or not the cell voltage satisfies a normal voltage range, and in response to a determination result, the processor may diagnose occurrence of a voltage deviation in abnormal cell voltage or occurrence of a voltage deviation in a normal cell voltage.

The invention relates to the technical field of battery detection, in particular to a lithium battery self-discharge detection method, system and equipment. According to the detection method, firstly, feature extraction is carried out on formation data of a to-be-detected sample to obtain a feature set of a to-be-detected sample set, then physical self-discharge detection is carried out on the feature set of the to-be-detected sample set through a physical self-discharge cell detection model, and after first abnormal cell data and first cell data are output, the first abnormal cell data and the second abnormal cell data are obtained. Carrying out chemical self-discharge detection on the first battery cell data through a chemical self-discharge battery cell detection model, outputting second abnormal battery cell data and normal battery cell data, and taking the battery cell corresponding to the first abnormal battery cell data and the second abnormal battery cell data as an abnormal battery cell through the above detection. And finally outputting the battery cell corresponding to the normal battery cell data. According to the scheme, different types of abnormal battery cells can be accurately distinguished, and the detection precision of the abnormal battery cells is effectively improved.

The invention discloses a model training method and a cell capacity prediction method and device, and relates to the field of batteries. The model training method comprises the steps that a first feature set is acquired, the first feature set is used for representing features associated with cell capacity in production parameters of sample cells, and the sample cells comprise normal cells and abnormal cells; screening features of which the distinguishing degree of the normal battery cell and the abnormal battery cell exceeds a first preset threshold value from the first feature set, and determining a second feature set; balancing the number of sample battery cells of which the battery cell capacities are located in each preset capacity interval in the second feature set, and determining a third feature set; and screening features having contribution to model training from the third feature set, determining a fourth feature set, and training the cell capacity prediction model through the fourth feature set. According to the method, the data for model training can be optimized, and the data quality is improved, so that the trained model can accurately predict the cell capacity of various capacity intervals.

Various solutions for accessing long periodicity cells for network energy saving with respect to user equipment and network apparatus in mobile communications are described. An apparatus may receive at least one information associated with a long-periodicity (LP) cell from a network node in a normal cell. The apparatus may perform a synchronization signal block (SSB)-based measurement according to the information to detect the LP cell. The apparatus may perform an access procedure with the LP cell.

The invention discloses an early diagnosis marker for B-cell lymphoma, a cross-species screening method based on lamprey and application, and relates to the technical field of molecular diagnosis. In the prior art, tissue biopsy is strong in invasiveness, and a traditional marker is low in early detection rate; in order to solve the problems that a large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large- When the expression quantity of the gene in a sample is greater than or equal to 1.8 times of that of a normal B cell (HMY2. CIR), the lymphoma is judged to be positive, and the minimally invasive early diagnosis efficiency is remarkably improved.

The invention relates to a three-level lymphoid structure model and a preparation method thereof, and belongs to the technical field of cell biology. The method for preparing the three-stage lymphoid structure model comprises the following steps: S1, inducing and activating peripheral blood mononuclear cells by using an extracellular matrix to obtain activated peripheral blood mononuclear cells; s2, the peripheral blood mononuclear cells and the mesenchymal stem cells activated in the step S1 are coated with hydrogel, and hydrogel microspheres are obtained; and S3, culturing T cells and B cells by using the hydrogel microspheres obtained in the step S2 to obtain the three-stage lymphatic structure. The three-level lymphoid structure model obtained by the invention maintains long-term stability in vitro, the form is normal, and the activity of T cells and B cells is strong. The method can be used for dynamically observing the three-level lymphoid structure in the subsequent research immunotherapy and drug screening process, is used for high-throughput experiments, effectively improves the efficiency of drug screening experiments, and is high in accuracy.

The invention belongs to the technical field of biological analysis, and particularly relates to nicking rolling circle amplification, self-loading multi-component nuclease (MNAzyme), a fluorescent RNA aptamer and application of the fluorescent RNA aptamer in miRNA detection. The invention provides an unmarked sensitive sensing platform, which is characterized in that cutting rolling circle amplification is integrated into a self-assembled multi-component nuclease (MNAzyme) and a fluorescent RNA (Ribonucleic Acid) aptamer, and the platform is used for monitoring miR-21. By utilizing the super-sensitivity, programmability and operability of the biosensing environment detection platform, the expression of miRNA in different breast cancer cells can be quantitatively detected, normal cells and different cancer cells can be distinguished, and the biosensing environment detection platform has huge potential in the aspects of biomedical research and clinical diagnosis.

The invention discloses a click type covalent drug as well as a regioselective delivery system and application thereof. The click-type covalent drug delivery system comprises a click-type covalent drug and a tumor region selective delivery system, and the click-type covalent drug is composed of aza-cyclic alkyne (DBCO), a small molecule drug and a linker and has a structure as shown in a formula 1. Optionally, the small molecule drugs are membrane protein inhibitors, immunomodulators, chemotherapeutic drugs and the like. The click-type covalent drug and the azide-labeled target cell are subjected to a click reaction to form a covalent bond to be combined on a cell membrane, so that the local drug concentration is improved, the drug retention time is prolonged, and the selective inhibition on the target cell is enhanced; the regioselective delivery system is formed by co-assembling an amphiphilic block polymer and a click type covalent drug, and is used for regioselective delivery. By means of the click type covalent drug, covalent binding of azide-labeled tumor cells is achieved, normal cells which are not labeled by azide are not affected, and toxic and side effects on normal tissue are reduced. # imgabs0 #

A memory device includes a peripheral circuit structure and a cell array structure vertically overlapping the peripheral circuit structure. The cell array structure includes a plurality of memory blocks divided into a normal cell region and a dummy cell region, and the dummy cell region includes a bit line through-electrode region. The peripheral circuit structure includes a row decoder region in which a unit row decoder circuit connected to each of n (n is a positive integer) memory blocks is arranged, and the bit line through-electrode region is disposed to correspond to the block height of the unit row decoder circuit.

The invention relates to a double-response EGFR (epidermal growth factor receptor) targeted paclitaxel liposome based on heat shock protein, which adopts a pH sensitive design and is doped with heat shock protein 90 (HSP90) responsive molecule gambogic acid (GA), the surface of the liposome is modified with an EGFR antibody, and the core of the liposome is packaged with paclitaxel (PTX). According to the double-response EGFR targeted paclitaxel liposome of the heat shock protein, triple negative breast cancer cells are accurately locked through a double targeting strategy, and cell surface specific recognition is achieved through an EGFR antibody; gambogic acid GA responds to HSP90 overexpression in cells to promote drug release; the pH sensitive characteristic ensures that the medicine is quickly released in an acidic tumor microenvironment, the treatment effect is enhanced, and normal cell damage is reduced. According to the invention, the specific quick response release of the medicine is realized, the treatment accuracy and safety are improved, and the preparation method has a remarkable application prospect in the aspect of preparing the medicine for treating the triple-negative breast cancer.

The invention discloses an anti-CD24 antibody and an application thereof. Specifically disclosed is an anti-CD24 antibody or antigen-binding fragment thereof, comprising a heavy chain variable region (SEQ ID NO: 1, 5, 9 or 13) and a light chain variable region (SEQ ID NO: 3, 7, 11 or 15). The anti-CD24 antibody (including a mouse monoclonal antibody and three humanized monoclonal antibodies) is obtained through a hybridoma technology and a CDR transplantation method. The anti-CD24 antibody has high affinity, can significantly inhibit the growth of tumors, has a tumor inhibition rate of 82.3%, has a significant anti-tumor curative effect, has a strong binding capacity with various tumor cells and tissues, does not bind with normal cells, and has good tumor selectivity. The antibody can be prepared into prevention and treatment drugs, diagnosis drugs, detection kits and the like for CD24 target related diseases, and has very wide clinical application prospects in the fields of tumor treatment and diagnosis and the like.

The invention relates to the technical field of biological medicines, and particularly discloses a transcription factor HOMEZ phosphorylation site specific antibody as well as a preparation method and application thereof. The specific antibody provided by the invention can specifically recognize phosphorylation of the 451st site threonine of HOMEZ in a tumor specimen, so that the prognosis condition of the tumor is judged, and a potential action target is provided for clinical diagnosis and treatment of the tumor; moreover, the specific antibody disclosed by the invention can be used for detecting the expression difference between normal cells and tumor cells in a Western blot experiment, and is beneficial to research on the effect of phosphorylation modification of HOMEZ protein in the occurrence and development process of tumor diseases; and the kit can also be used for detecting the phosphorylation level of the HOMEZ protein in a clinical specimen through experiments such as immunofluorescence and immunohistochemical staining, and has a wide clinical application prospect in the aspects of disease diagnosis, treatment, prognosis judgment and the like.

The invention relates to the technical field of image processing, in particular to a stomach cancer tissue typing auxiliary recognition method based on digital pathological sections. According to the method, morphological feature recognition is carried out on edge information in a grayscale image of a slice, and normal cell edges and abnormal cell edges are screened out according to the size of morphological feature indexes and the morphology of a cell edge curve. A first abnormal area and a second abnormal area are screened out according to the proximity relation, then enhancement coefficients of the two abnormal areas are calculated and enhanced, and a gastric cancer tissue typing recognition result is obtained according to the enhanced stomach pathology image. According to the invention, the object of the enhancement process is only limited to the abnormal region, and different degrees of enhancement are realized for different types of abnormal regions, so that the calculation amount of the enhancement process is reduced, the enhancement process has pertinence, excessive enhancement cannot be caused, and a clear slice image is obtained for tissue typing identification; and the tissue typing recognition efficiency is improved.

The application discloses a cell detection method and system based on deep learning and machine vision, which comprises the following steps: cutting a cervical liquid-based cell pathology digital image into a plurality of sub-images to form a sub-image set; inputting the sub-image set into a normal cell detection model and a lesion cell detection model respectively, and identifying normal cells and lesion cells and their categories; selecting an overlapping area of the normal cells and the lesion cells, and performing secondary classification on the overlapping area through a classification model; performing threshold segmentation on granulocytes in the cervical liquid-based cell pathology digital image to obtain all possible granulocyte targets, filtering to determine final granulocyte targets, and counting and determining the number of the granulocytes. The application solves the problem that the detection model in the prior art has poor detection effect due to the imbalance of normal cell and lesion cell categories, improves the accuracy of cell identification, and realizes accurate detection and identification of cervical liquid-based cells in combination with accurately identified granulocytes.

The invention belongs to the technical field of medicinal chemistry, and particularly discloses a novel tubulin and metalloproteinase double-target inhibitor as well as a preparation method and application of the novel tubulin and metalloproteinase double-target inhibitor. A novel tubulin and metalloproteinase double-target inhibitor is obtained as a compound with a targeting function. A verification result shows that the synthesized target compound shows good anti-proliferative activity on tested cancer cells, 15j has the optimal anti-tumor activity, the IC50 value range of the target compound is 0.154-0.296 mu M, and the tumor inhibition rate of the target compound on human lung cancer transplantation tumors is 74.7% (20 mg / kg). Besides, the anti-proliferative activity of the 15j to cis-platinum drug-resistant cells A549 / CDDP is 136.70 times that of the cis-platinum, the anti-proliferative activity of the 15j to adriamycin drug-resistant cells MCF-7 / DOX is 71.14 times that of the adriamycin, and the toxicity of the 15j to human normal cells (LO2 and MCF-10A) is lower than that of positive drugs such as the cis-platinum, the adriamycin and the paclitaxel. Therefore, the compound has the potential purpose of targeted treatment of lung cancer.

The invention discloses a preparation method and application of a copper oxide coated adriamycin nano-material, the prepared drug-loaded nano-material has good antitumor activity, and the preparation scheme comprises synthesis of Cu2O nano-particles, synthesis of Cu2O-NH2 nano-particles and drug loading. The copper oxide coated doxorubicin nano-material prepared by the invention can effectively load doxorubicin medicine into nano-particles, so that the medicine transfer efficiency is improved, and the effect of the medicine in vivo is enhanced. The nano material disclosed by the invention can accurately regulate and control the release rate of adriamycin under different buffer solution pH values or different time points, so that the sustained release of the medicine under specific conditions is realized, and the curative effect of the medicine is improved. By modifying the surface of copper oxide, targeted delivery of the medicine can be realized, the medicine can be more accurately delivered to breast cancer cells, the influence on normal cells is reduced, the treatment effect is improved, and the effective service life of the medicine is prolonged.

The invention discloses a method for detecting, identifying and counting cerebrospinal fluid cell images, which comprises the following steps of: firstly, acquiring a high-quality digital image of a cerebrospinal fluid cell smear through a microscope, and then revealing edges and other areas for distinguishing cells in the image through gradient value calculation; furthermore, through calculation of a local contrast change rate, microscopic change of the cell image is accurately captured, and normal cells and cells with abnormal forms are effectively distinguished; and furthermore, normal cells and abnormal cells are counted to obtain a counting result, so that medical personnel can be better helped to identify the illness state of the patient, and powerful patient medical record information is provided for subsequent medical assistance.

The invention belongs to the technical field of analytical chemistry, and relates to a method for identifying and detecting endogenous mercaptan of a high-activity oxidized nano-enzyme based on machine learning, which comprises the following steps: firstly, preparing a Mnx (DTPMP) nano-enzyme, then constructing a sensor array of one nano-enzyme, four reaction times, three targets and six parallel samples, and detecting the endogenous mercaptan in the Mnx (DTPMP) nano-enzyme. Constructing a sensor array of one nano enzyme, four reaction times, 7 concentrations and 6 parallel samples for each endogenous mercaptan; and finally, analyzing the data through hierarchical clustering analysis, linear discriminant analysis and a support vector machine to obtain an LDA score chart, an HCA map, an SVM confusion matrix and a concentration prediction map of the endogenous mercaptan. After a sample to be detected is subjected to a chromogenic reaction, the absorbance is measured, and the type and concentration of the endogenous mercaptan of the sample to be detected can be distinguished according to the obtained spectrum. The kit has good anti-interference performance, normal cells and cancer cells can be accurately identified according to the content of glutathione in the cells, and the severity of diseases can be judged according to the content of homocysteine in serum.

The invention discloses a transparent culture device supporting cell orientation and electrophysiological signal in-situ monitoring and a preparation method. The transparent culture device comprises a transparent substrate, a microelectrode structure is prepared on the transparent substrate, oriented biological fibers are prepared on the microelectrode structure, and a cell culture cavity used for containing cell culture fluid is formed above the oriented biological fibers and the microelectrode structure; the directional biological fiber and microelectrode structure arrangement mode is designed according to requirements and is printed and formed, and a transparent substrate material is selected according to requirements; according to the invention, cell orientation and electrophysiological signal in-situ monitoring are supported on the transparent culture surface through electrostatic printing, and normal cell observation is not affected.